Read the story here. Advertise at Before It's News here.
Profile image
By Streetwise-The Energy Report (Reporter)
Contributor profile | More stories
Story Views
Last hour:
Last 24 hours:

Lithium Co.'s Recent News May Drive the Stock Higher, Expert Says

% of readers think this story is Fact. Add your two cents.

Source: Clive Maund 04/29/2024

In light of this morning’s news, Technical Analyst Clive Maund shares an update on IberAmerican Lithium Corp. to explain why he believes now might be the time to add positions.

IberAmerican Lithium Corp. (IBER:CBOE; IBRLF:OTCQB) was the subject of an article posted on March 11, when the stock was recommended on both fundamental and technical grounds. In the event, the recommendation was rather too early as it went on to drop to a lower level before completing its odd-shaped Cup and Handle base.

Yet the basic idea was correct, for it has just last week broken out upside from the pattern due to the rapidly improving fundamental situation for the company so that we are now up on where we bought and the reason for this update is that the company came out with a range of positive news announcements early today that are thought like to drive the stock price higher still.

The news out today included a business combination with Strategic Minerals Europe Corp. Upon completion of this Proposed Transaction, the company intends to resume production at Strategic Minerals’ flagship property, the Penouta Project. In addition, the company will vertically integrate with a wholly owned subsidiary and change its name to IberAmerican Resources Inc., which will lead to it not being associated solely with lithium. Lastly, the company will engage Spark Newswire to generate publicity and raise its profile.

Probably the most important points in the news release that are likely to impact the stock price, perhaps immediately, are these statements:

After completion of the Proposed Transaction (the business combination with Strategic Minerals Europe), the Company is committed to implementing crucial capital improvements to optimize production efficiencies within the expansive hard rock resource located in Section C so that the company may restart its exploitation as soon as possible after the lifting of the provisional suspensión.”

And the statement by CEO Campbell Becher:

“Upon completion of the Proposed Transaction, we intend to promptly resume production in Section B, generating immediate cash flow.”

Now, we will turn our attention to the progress of the company’s stock by looking at its latest 8-month stock chart. On this chart, we can see that after we bought on about March 11, the price continued to drift lower within an extended Handle of the odd-shaped Cup and Handle base.

Over a week ago, there was an alarming but short-lived drop to 7 cents, which may have been an “organized raid” designed to shake out weak holders of the stock ahead of the strong rally that followed. After this freak drop, the stock quickly recovered and then became much more active, breaking out of the Handle of the Cup and Handle base last week. The remaining Hurdle to clear before the stock is more free to advance is the resistance shown at the upper boundary of the entire pattern, and it is thought that the big news out this morning is likely to drive the stock above this resistance.

With the picture for IberAmerican now considerably clearer and brighter, we stay long, and this is thought to be a good point to buy or add to positions.

IberAmerican Lithium’s website.

IberAmerican Lithium Corp. (IBER:CBOE; IBRLF:OTCQB) closed at CA$0.17 on April 26, 2024.

Sign up for our FREE newsletter at:

Important Disclosures:

  1. IberAmerican Lithium Corp. has a consulting relationship with an affiliate of Streetwise Reports, and pays a monthly consulting fee between US$8,000 and US$20,000.
  2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of IberAmerican Lithium Corp.
  3. Author Certification and Compensation: [Clive Maund of] is being compensated as an independent contractor by Street Smart, an affiliate of Streetwise Reports, for writing this article. Maund received his UK Technical Analysts’ Diploma in 1989. The recommendations and opinions expressed in this content accurately reflect the personal, independent, and objective views of the author regarding any and all of the designated securities discussed. No part of the compensation received by the author was, is, or will be directly or indirectly related to the specific recommendations or views expressed
  4. Statements and opinions expressed are the opinions of the author and not of Streetwise Reports, Street Smart, or their officers. The author is wholly responsible for the accuracy of the statements. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Any disclosures from the author can be found below. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
  5. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here. Disclosures

The above represents the opinion and analysis of Mr. Maund, based on data available to him, at the time of writing. Mr. Maund’s opinions are his own, and are not a recommendation or an offer to buy or sell securities. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund’s opinions on the market and stocks cannot be only be construed as a recommendation or solicitation to buy and sell securities.

( Companies Mentioned: IBER:CBOE; IBRLF:OTCQB, )


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Lion’s Mane Mushroom

Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, But it benefits growth of Essential Gut Flora, further enhancing your Vitality.

Our Formula includes:

Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity.

Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins.

Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system.

Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome.

Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function.

Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules. Today Be 100% Satisfied Or Receive A Full Money Back Guarantee Order Yours Today By Following This Link.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Load more ...




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.